Prostate Cancer Evaluation of TaRgets in Genito Urinary Screening Program

Metastatic Castration Resistant Prostate Cancer Patients Clinical Trial

— PETRUS  

Official title:

Prostate Cancer Evaluation of TaRgets in Genito Urinary Screening Program

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01786031
• Other study ID #: 2012-A00668-35
• Status: Completed
• Phase: N/A
• First received: December 3, 2012
• Last updated: February 5, 2016
• Start date: December 2012
• Est. completion date: January 2015

Study information

• Verified date: February 2016
• Source: Gustave Roussy, Cancer Campus, Grand Paris
• Contact: n/a
• Is FDA regulated: No
• Health authority: France: Agence Nationale de Sécurité du Médicament et des produits de santé
• Study type: Interventional

Clinical Trial Summary

Toward personalised treatment in early metastatic prostate cancer based on the assessment of biomarkers in cancer tissue samples and circulating tumour cells.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 55
• Est. completion date: January 2015
• Est. primary completion date: January 2015
• Accepts healthy volunteers: No
• Gender: Male
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Prostate Cancer patients

• Castration Resistant

• Prostatic tissue available

• Metastasis which may be biopsied

Exclusion Criteria:

Study Design

Endpoint Classification: Bio-availability Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic

Related Conditions & MeSH terms

• Metastatic Castration Resistant Prostate Cancer Patients
• Prostatic Neoplasms

Intervention

Other:
• metastasis biopsy

Locations

Country	Name	City	State
France	Institut Gustave Roussy	Villejuif	Val de Marne

Sponsors (1)

Lead Sponsor	Collaborator
Gustave Roussy, Cancer Campus, Grand Paris

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Biomarker	success to evaluate at least one molecular analysis in tumor tissues (prostate and/or metastatic site) AND in CTC	assessed at the end of recruitment, up to 2 years	No